GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Balance Sheet History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
Equity - Authorised | ₹237 Cr | ₹237 Cr | ₹237 Cr | ₹237 Cr | ₹237 Cr |
Equity - Issued | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
Equity Paid Up | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 |
Share Warrants & Outstandings | ₹18 Cr | ₹16 Cr | ₹22 Cr | ₹14 Cr | ₹11 Cr |
Total Reserves | ₹9,428 Cr | ₹9,042 Cr | ₹7,015 Cr | ₹6,029 Cr | ₹5,566 Cr |
Securities Premium | ₹1,685 Cr | ₹1,685 Cr | ₹1,685 Cr | ₹1,685 Cr | ₹1,685 Cr |
Capital Reserves | ₹0.10 Cr | ₹0.10 Cr | ₹0.10 Cr | ₹0.10 Cr | ₹0.10 Cr |
Profit & Loss Account Balance | ₹9,457 Cr | ₹9,211 Cr | ₹7,234 Cr | ₹6,330 Cr | ₹5,615 Cr |
General Reserves | ₹146 Cr | ₹146 Cr | ₹146 Cr | ₹146 Cr | ₹146 Cr |
Other Reserves | ₹-1,860 Cr | ₹-2,000 Cr | ₹-2,050 Cr | ₹-2,132 Cr | ₹-1,880 Cr |
Reserve excluding Revaluation Reserve | ₹9,428 Cr | ₹9,042 Cr | ₹7,015 Cr | ₹6,029 Cr | ₹5,566 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹9,474 Cr | ₹9,087 Cr | ₹7,065 Cr | ₹6,071 Cr | ₹5,605 Cr |
Minority Interest | ₹365 Cr | ₹351 Cr | ₹-0.35 Cr | ₹-0.39 Cr | ₹-0.38 Cr |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | - | - | - | - |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | - | - |
Unsecured Loans | ₹3,852 Cr | ₹2,572 Cr | ₹3,889 Cr | ₹4,043 Cr | ₹3,574 Cr |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | ₹729 Cr | ₹1,017 Cr | ₹1,643 Cr | ₹1,457 Cr |
Long Term Loan in Foreign Currency | ₹2,806 Cr | ₹2,572 Cr | ₹2,095 Cr | - | - |
Loans - Banks | ₹1,191 Cr | - | ₹1,062 Cr | ₹1,295 Cr | ₹1,314 Cr |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | ₹1,488 Cr | ₹1,374 Cr |
Other Unsecured Loan | ₹-146 Cr | ₹-729 Cr | ₹-286 Cr | ₹-383 Cr | ₹-572 Cr |
Deferred Tax Assets / Liabilities | ₹-1,763 Cr | ₹-1,655 Cr | ₹-1,506 Cr | ₹-1,439 Cr | ₹-1,383 Cr |
Deferred Tax Assets | ₹2,048 Cr | ₹1,938 Cr | ₹1,823 Cr | ₹1,754 Cr | ₹1,755 Cr |
Deferred Tax Liability | ₹285 Cr | ₹283 Cr | ₹318 Cr | ₹315 Cr | ₹372 Cr |
Other Long Term Liabilities | ₹592 Cr | ₹352 Cr | ₹421 Cr | ₹429 Cr | ₹89 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | - | - | - | - | - |
Total Non-Current Liabilities | ₹2,681 Cr | ₹1,270 Cr | ₹2,804 Cr | ₹3,033 Cr | ₹2,280 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹2,392 Cr | ₹2,289 Cr | ₹2,238 Cr | ₹2,126 Cr | ₹2,221 Cr |
Sundry Creditors | ₹2,392 Cr | ₹2,289 Cr | ₹2,238 Cr | ₹2,126 Cr | ₹2,221 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹1,691 Cr | ₹1,446 Cr | ₹886 Cr | ₹1,002 Cr | ₹1,013 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | - | - | - | - | - |
Interest Accrued But Not Due | ₹43 Cr | ₹14 Cr | ₹18 Cr | ₹19 Cr | ₹23 Cr |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹1,647 Cr | ₹1,433 Cr | ₹868 Cr | ₹982 Cr | ₹990 Cr |
Short Term Borrowings | ₹350 Cr | ₹370 Cr | ₹513 Cr | ₹443 Cr | ₹303 Cr |
Secured ST Loans repayable on Demands | - | - | - | - | ₹6.11 Cr |
Working Capital Loans- Sec | - | - | - | - | ₹6.11 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | ₹350 Cr | ₹370 Cr | ₹513 Cr | ₹443 Cr | ₹291 Cr |
Short Term Provisions | ₹613 Cr | ₹585 Cr | ₹564 Cr | ₹556 Cr | ₹484 Cr |
Proposed Equity Dividend | - | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹106 Cr | ₹93 Cr | ₹50 Cr | ₹41 Cr | ₹46 Cr |
Provision for post retirement benefits | ₹97 Cr | ₹98 Cr | ₹115 Cr | ₹112 Cr | ₹93 Cr |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹411 Cr | ₹394 Cr | ₹399 Cr | ₹403 Cr | ₹345 Cr |
Total Current Liabilities | ₹5,046 Cr | ₹4,689 Cr | ₹4,201 Cr | ₹4,126 Cr | ₹4,021 Cr |
Total Liabilities | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr | ₹13,229 Cr | ₹11,906 Cr |
ASSETS | |||||
Gross Block | ₹11,296 Cr | ₹10,213 Cr | ₹8,732 Cr | ₹8,270 Cr | ₹6,527 Cr |
Less: Accumulated Depreciation | ₹5,094 Cr | ₹4,326 Cr | ₹3,603 Cr | ₹3,241 Cr | ₹2,857 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹6,202 Cr | ₹5,887 Cr | ₹5,129 Cr | ₹5,029 Cr | ₹3,670 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹1,115 Cr | ₹921 Cr | ₹1,218 Cr | ₹1,091 Cr | ₹1,234 Cr |
Non Current Investments | ₹45 Cr | ₹50 Cr | ₹25 Cr | ₹25 Cr | ₹30 Cr |
Long Term Investment | ₹45 Cr | ₹50 Cr | ₹25 Cr | ₹25 Cr | ₹30 Cr |
Quoted | ₹0.07 Cr | ₹0.05 Cr | ₹0.07 Cr | ₹0.03 Cr | ₹0.10 Cr |
Unquoted | ₹45 Cr | ₹50 Cr | ₹25 Cr | ₹25 Cr | ₹30 Cr |
Long Term Loans & Advances | ₹190 Cr | ₹161 Cr | ₹146 Cr | ₹124 Cr | ₹94 Cr |
Other Non Current Assets | ₹3.46 Cr | ₹6.70 Cr | ₹28 Cr | ₹26 Cr | ₹16 Cr |
Total Non-Current Assets | ₹7,692 Cr | ₹7,115 Cr | ₹6,709 Cr | ₹6,425 Cr | ₹5,209 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | - | - | - | - | - |
Quoted | - | - | - | - | - |
Unquoted | - | - | - | - | - |
Inventories | ₹2,978 Cr | ₹2,500 Cr | ₹2,277 Cr | ₹2,136 Cr | ₹2,252 Cr |
Raw Materials | ₹817 Cr | ₹703 Cr | ₹528 Cr | ₹635 Cr | ₹637 Cr |
Work-in Progress | ₹455 Cr | ₹402 Cr | ₹439 Cr | ₹361 Cr | ₹374 Cr |
Finished Goods | ₹1,069 Cr | ₹846 Cr | ₹839 Cr | ₹725 Cr | ₹853 Cr |
Packing Materials | ₹299 Cr | ₹269 Cr | ₹230 Cr | ₹193 Cr | ₹183 Cr |
Stores Ā and Spare | ₹114 Cr | ₹104 Cr | ₹107 Cr | ₹85 Cr | ₹81 Cr |
Other Inventory | ₹224 Cr | ₹174 Cr | ₹133 Cr | ₹136 Cr | ₹123 Cr |
Sundry Debtors | ₹4,099 Cr | ₹3,101 Cr | ₹2,572 Cr | ₹2,409 Cr | ₹2,195 Cr |
Debtors more than Six months | ₹368 Cr | ₹302 Cr | ₹396 Cr | - | - |
Debtors Others | ₹3,872 Cr | ₹2,929 Cr | ₹2,283 Cr | ₹2,505 Cr | ₹2,271 Cr |
Cash and Bank | ₹1,470 Cr | ₹1,412 Cr | ₹1,139 Cr | ₹1,111 Cr | ₹938 Cr |
Cash in hand | ₹1.13 Cr | ₹1.69 Cr | ₹1.61 Cr | ₹1.66 Cr | ₹1.04 Cr |
Balances at Bank | ₹1,469 Cr | ₹1,410 Cr | ₹1,138 Cr | ₹1,110 Cr | ₹937 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹361 Cr | ₹297 Cr | ₹671 Cr | ₹603 Cr | ₹765 Cr |
Interest accrued on Investments | - | - | - | - | - |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹228 Cr | ₹220 Cr | ₹220 Cr | ₹146 Cr | ₹132 Cr |
Other current_assets | ₹133 Cr | ₹78 Cr | ₹451 Cr | ₹458 Cr | ₹633 Cr |
Short Term Loans and Advances | ₹967 Cr | ₹972 Cr | ₹700 Cr | ₹544 Cr | ₹547 Cr |
Advances recoverable in cash or in kind | ₹413 Cr | ₹457 Cr | ₹633 Cr | ₹508 Cr | ₹455 Cr |
Advance income tax and TDS | - | - | - | ₹2.65 Cr | - |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹554 Cr | ₹516 Cr | ₹68 Cr | ₹34 Cr | ₹93 Cr |
Total Current Assets | ₹9,874 Cr | ₹8,282 Cr | ₹7,360 Cr | ₹6,804 Cr | ₹6,697 Cr |
Net Current Assets (Including Current Investments) | ₹4,828 Cr | ₹3,593 Cr | ₹3,159 Cr | ₹2,678 Cr | ₹2,676 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr | ₹13,229 Cr | ₹11,906 Cr |
Contingent Liabilities | ₹337 Cr | ₹361 Cr | ₹384 Cr | ₹271 Cr | ₹74 Cr |
Total Debt | ₹4,348 Cr | ₹3,670 Cr | ₹4,687 Cr | ₹4,869 Cr | ₹4,449 Cr |
Book Value | - | 321.45 | 249.60 | 214.65 | 198.27 |
Adjusted Book Value | 335.13 | 321.45 | 249.60 | 214.65 | 198.27 |
Compare Balance Sheet of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹30,232.1 Cr | 4% | 6.2% | 118% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 4% |
6.2% |
118% |
SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses